Publication of 2022 EORTC Annual Report
This comprehensive report collects the most relevant and up-to-date [...]
EORTC is supporting Clinical Trials Day on 20th May
Since 2014, Clinical Trials Day celebrates achievements from the [...]
Studying long-term survivors of glioblastoma may pave the way to better treatment
Brussels, May 10, 2023 – Despite major medical advances, glioblastoma [...]
HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer
EORTC will coordinate an evening symposium and a workshop [...]
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC) GalleryFDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
Approval based on KEYNOTE-091 trial, which demonstrated a clinically [...]
Completion of Patient Recruitment for International TIGER Study
Brussels, 19 December 2022 - EORTC and Alliance for [...]
EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
In June 2022, EORTC and Cancer Trials Ireland (CTI) [...]
EORTC, SPO and AICIB establish a partnership to promote cancer clinical research in Portugal
Brussels/Porto/ Lisbon, 2 December 2022 - The European Organisation [...]
EORTC and Walgreens Boots Alliance announce continued partnership in support of E²-RADIatE platform
[photo from EORTC’s 60th Anniversary Gala Dinner in Brussels, [...]
Results of two EORTC studies have been published in NEJM and the Lancet Oncology
The results of two studies led by EORTC have [...]
